Patents by Inventor Ludmila Buzhansky
Ludmila Buzhansky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11773060Abstract: A formulation includes an active agent, a thickening/solidifying agent, and an antioxidant. The active agent is 9-cis-?-carotene (9CBC) or a derivative thereof of the following formula: where R2 is H or methyl; X is optionally substituted with one or more methyl groups; n is an integer of 0-16; and the asterisk represents the point of attachment to the cyclohexene ring.Type: GrantFiled: October 11, 2021Date of Patent: October 3, 2023Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Ehud Gazit, Ludmila Buzhansky, Michael Ioffe, Alon Sayer
-
Publication number: 20220098149Abstract: A formulation includes an active agent, a thickening/solidifying agent, and an antioxidant. The active agent is 9-cis-?-carotene (9CBC) or a derivative thereof of the following formula: where R2 is H or methyl; X is optionally substituted with one or more methyl groups; n is an integer of 0-16; and the asterisk represents the point of attachment to the cyclohexene ring.Type: ApplicationFiled: October 11, 2021Publication date: March 31, 2022Inventors: Ehud Gazit, Ludmila Buzhansky, Michael Ioffe, Alon Sayer
-
Patent number: 11285115Abstract: Compositions comprising self-assembled hydrogel particles formed of short peptides which comprise one or more aromatic amino acid residue(s) in an inverted emulsion are disclosed. Such hydrogel particles which encapsulate an active agent and uses thereof in therapeutic and diagnostic applications are also disclosed.Type: GrantFiled: February 27, 2014Date of Patent: March 29, 2022Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Rafael Ischakov, Ludmila Buzhansky, Lihi Adler-Abramovich, Ehud Gazit
-
Patent number: 11261230Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: June 28, 2020Date of Patent: March 1, 2022Assignees: RAMOT AT TEL AVIV UNIVERSITY LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Patent number: 11142496Abstract: The present invention relates to a method for total chemical synthesis of 9-cis-?-carotene (9CBC), and further provides stable formulations thereof.Type: GrantFiled: May 21, 2017Date of Patent: October 12, 2021Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Ehud Gazit, Ludmila Buzhansky, Michael Ioffe, Alon Sayer
-
Publication number: 20200325203Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: June 28, 2020Publication date: October 15, 2020Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY
-
Patent number: 10723780Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: March 19, 2019Date of Patent: July 28, 2020Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Publication number: 20190367451Abstract: The present invention relates to a method for total chemical synthesis of 9-cis-?-carotene (9CBC), and further provides stable formulations thereof.Type: ApplicationFiled: May 21, 2017Publication date: December 5, 2019Inventors: Ehud Gazit, Ludmila Buzhansky, Michael Ioffe, Alon Sayer
-
Publication number: 20190276513Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: March 19, 2019Publication date: September 12, 2019Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY
-
Patent number: 10266579Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: September 10, 2015Date of Patent: April 23, 2019Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Patent number: 10245351Abstract: Hybrid hydrogels formed of a plurality of peptides that are capable of self-assembling into a hydrogel in an aqueous solution and a biocompatible polymer that is characterized by high swelling capability, high elasticity and low mechanical strength are disclosed, with exemplary hybrid hydrogels being formed of a plurality of aromatic dipeptides and hyaluronic acid. The hybrid hydrogels are characterized by controllable mechanical and biological properties which can be adjusted by controlling the concentration ratio of the peptides and the polymer, and which average the mechanical and biological properties of the peptides and the polymer. Processes of preparing the hydrogels and uses thereof in pharmaceutical, cosmetic or cosmeceutic applications such as tissue engineering and/or regeneration are further disclosed.Type: GrantFiled: March 20, 2017Date of Patent: April 2, 2019Assignee: Technology Innovation Momentum Fund (Israel) Limited PartnershipInventors: Moran Aviv, Ludmila Buzhansky, Shmuel Einav, Zvi Nevo, Ehud Gazit, Lihi Adler-Abramovich
-
Publication number: 20170298113Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: September 10, 2015Publication date: October 19, 2017Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY
-
Publication number: 20170189582Abstract: Hybrid hydrogels formed of a plurality of peptides that are capable of self-assembling into a hydrogel in an aqueous solution and a biocompatible polymer that is characterized by high swelling capability, high elasticity and low mechanical strength are disclosed, with exemplary hybrid hydrogels being formed of a plurality of aromatic dipeptides and hyaluronic acid. The hybrid hydrogels are characterized by controllable mechanical and biological properties which can be adjusted by controlling the concentration ratio of the peptides and the polymer, and which average the mechanical and biological properties of the peptides and the polymer. Processes of preparing the hydrogels and uses thereof in pharmaceutical, cosmetic or cosmeceutic applications such as tissue engineering and/or regeneration are further disclosed.Type: ApplicationFiled: March 20, 2017Publication date: July 6, 2017Applicant: Technology Innovation Momentum Fund (Israel) Limited PartnershipInventors: Moran AVIV, Ludmila BUZHANSKY, Shmuel EINAV, Zvi NEVO, Ehud GAZIT, Lihi ADLER-ABRAMOVICH
-
Patent number: 9630989Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipetide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.Type: GrantFiled: July 22, 2015Date of Patent: April 25, 2017Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Ehud Gazit, Yaniv Amir, Ludmila Buzhansky, Ulrich Abel, Anat Frydman-Marom
-
Patent number: 9610353Abstract: Hybrid hydrogels formed of a plurality of peptides that are capable of self-assembling into a hydrogel in an aqueous solution and a biocompatible polymer that is characterized by high swelling capability, high elasticity and low mechanical strength are disclosed, with exemplary hybrid hydrogels being formed of a plurality of aromatic dipeptides and hyaluronic acid. The hybrid hydrogels are characterized by controllable mechanical and biological properties which can be adjusted by controlling the concentration ratio of the peptides and the polymer, and which average the mechanical and biological properties of the peptides and the polymer. Processes of preparing the hydrogels and uses thereof in pharmaceutical, cosmetic or cosmeceutic applications such as tissue engineering and/or regeneration are further disclosed.Type: GrantFiled: July 6, 2015Date of Patent: April 4, 2017Assignee: Technology Innovation Momentum Fund (Israel) Limited PartnershipInventors: Moran Aviv, Ludmila Buzhansky, Shmuel Einav, Zvi Nevo, Ehud Gazit, Lihi Adler-Abramovich
-
Publication number: 20160008291Abstract: Compositions comprising self-assembled hydrogel particles formed of short peptides which comprise one or more aromatic amino acid residue(s) in an inverted emulsion are disclosed. Such hydrogel particles which encapsulate an active agent and uses thereof in therapeutic and diagnostic applications are also disclosed.Type: ApplicationFiled: February 27, 2014Publication date: January 14, 2016Inventors: Rafael ISCHAKOV, Ludmila BUZHANSKY, Lihi ADLER-ABRAMOVICH, Ehud GAZIT
-
Publication number: 20150322110Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipetide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.Type: ApplicationFiled: July 22, 2015Publication date: November 12, 2015Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Ehud GAZIT, Yaniv Amir, Ludmila Buzhansky, Ulrich Abel, Anat Frydman-Marom
-
Publication number: 20150306229Abstract: Hybrid hydrogels formed of a plurality of peptides that are capable of self-assembling into a hydrogel in an aqueous solution and a biocompatible polymer that is characterized by high swelling capability, high elasticity and low mechanical strength are disclosed, with exemplary hybrid hydrogels being formed of a plurality of aromatic dipeptides and hyaluronic acid. The hybrid hydrogels are characterized by controllable mechanical and biological properties which can be adjusted by controlling the concentration ratio of the peptides and the polymer, and which average the mechanical and biological properties of the peptides and the polymer. Processes of preparing the hydrogels and uses thereof in pharmaceutical, cosmetic or cosmeceutic applications such as tissue engineering and/or regeneration are further disclosed.Type: ApplicationFiled: July 6, 2015Publication date: October 29, 2015Applicant: Technology Innovation Momentum Fund (Israel) Limited PartnershipInventors: Moran AVIV, Ludmila BUZHANSKY, Shmuel EINAV, Zvi NEVO, Ehud GAZIT, Lihi ADLER-ABRAMOVICH
-
Patent number: 9096645Abstract: Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed.Type: GrantFiled: November 15, 2011Date of Patent: August 4, 2015Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Ehud Gazit, Yaniv Amir, Ludmila Buzhansky, Ulrich Abel, Anat Frydman-Marom
-
Patent number: 9074095Abstract: Hybrid hydrogels formed of a plurality of peptides that are capable of self-assembling into a hydrogel in an aqueous solution and a biocompatible polymer that is characterized by high swelling capability, high elasticity and low mechanical strength are disclosed, with exemplary hybrid hydrogels being formed of a plurality of aromatic dipeptides and hyaluronic acid. The hybrid hydrogels are characterized by controllable mechanical and biological properties which can be adjusted by controlling the concentration ratio of the peptides and the polymer, and which average the mechanical and biological properties of the peptides and the polymer. Processes of preparing the hydrogels and uses thereof in pharmaceutical, cosmetic or cosmeceutic applications such as tissue engineering and/or regeneration are further disclosed.Type: GrantFiled: June 2, 2011Date of Patent: July 7, 2015Assignee: Technology Innovation Momentum Fund (Israel) Limited PartnershipInventors: Moran Aviv, Ludmila Buzhansky, Shmuel Einav, Zvi Nevo, Ehud Gazit, Lihi Adler-Abramovich